Format

Send to

Choose Destination
See comment in PubMed Commons below
Endocr Dev. 2011;21:85-90. doi: 10.1159/000328133. Epub 2011 Aug 22.

Allele-specific gene silencing in osteogenesis imperfecta.

Author information

1
Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Osten.ljunggren@medsci.uu.se

Abstract

OI is caused by mutations in the genes encoding for collagen type I COL1A1 and COL1A2, respectively. The patients suffer from bone fragility, and the severity can range from mild, with fractures in the youth, to lethal forms. Today, there is no effective treatment for the disorder. OI is caused by dominant negative mutations. A tempting approach to treat the disease would be to silence the allele carrying the mutation. This could in theory be done with siRNAs. Today, more than 800 various mutations are reported, and to create siRNA against a specific mutation is difficult. Instead, by developing siRNA against common polymorphic variations, it would be possible to silence the mutation by a standardized method regardless where the mutation is located on the allele. If the concept of allele-specific gene silencing by inhibitory RNA directed towards dominant negative mutations could be proven, this might be a novel approach to gene therapy in OI.

PMID:
21865757
DOI:
10.1159/000328133
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center